News

The U.S. Food and Drug Administration (FDA) has approved Tyvaso DPI, a dry powder, inhaled formulation of treprostinil, to improve exercise ability in people with pulmonary arterial hypertension (PAH) or pulmonary hypertension associated with interstitial lung disease (PH-ILD). Tyvaso DPI is now the only dry powder inhaler approved…

Sacubitril/valsartan, a fixed-dose combination oral therapy approved for heart failure, was found to improve right heart function and lower pulmonary blood pressure, according to a new pooled analysis of multiple studies. This meta-analysis supports a new therapeutic role for sacubitril/valsartan for people with pulmonary hypertension (PH) associated with heart…

Even with modern advances in treatments, many people in the U.S. with pulmonary arterial hypertension (PAH) are at an “unacceptably high” risk of mortality, a new study shows. The study, “Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry,” was…

Aerovate Therapeutics‘ AV-101, an inhaled formulation of imatinib for treating pulmonary arterial hypertension (PAH), was well tolerated in healthy adult volunteers enrolled in a Phase 1 trial. Study data also indicate AV-101, which delivers the medication directly to the lungs, reduced its systemic (whole body) exposure. This is…

Switching from Tracleer (bosentan) to Opsumit (macitentan) improved physical abilities with fewer side effects in some adults with pulmonary arterial hypertension (PAH), a study showed. Replacing Tracleer with Opsumit may be a feasible treatment option in PAH patients who did not fully respond to Tracleer alone or…

The blood levels of a signaling molecule called fibroblast growth factor 21 (FGF21) are significantly reduced in people with high-altitude pulmonary hypertension (PH) and in mice with hypoxia-induced PH, a study shows. Hypoxia refers to low oxygen conditions and chronic hypoxia is a common cause of PH. Also, treatment with…

The levels of blood-circulating inflammatory molecules differ between men and women with pulmonary arterial hypertension (PAH) and correlate with disease severity, a study suggests. Notably, the levels of two proteins — called IL-6 and MIP-1alpha — were predictors of poorer survival statistics. These findings suggest that patient stratification may…

The gut microbiota of patients with chronic thromboembolic pulmonary hypertension (CTEPH) differs from that of healthy individuals, and this perhaps explains why there also is more inflammation, a Japanese study found. The findings provide new information on the way CTEPH may develop. The study, “Altered gut microbiota and…

To celebrate World Pulmonary Hypertension Day on May 5, Ferrer and the European Pulmonary Hypertension Association (PHA Europe) have launched the PHantasticals campaign to raise public awareness about rare and chronic lung diseases like pulmonary hypertension (PH). The campaign features a collection of mermaid characters called the…

Chiesi Farmaceutici has acquired the worldwide rights to a number of investigational antibodies that may be able to treat pulmonary arterial hypertension (PAH) from the developer, Allinaire Therapeutics. All of the antibodies act against the endothelial monocyte-activating polypeptide (EMAP II), a pro-inflammatory molecule that is thought to…

A Russian military plane crash near Tetiana Zamorska’s home in Kyiv, Ukraine, was a sign that it was time for her and her family to leave. The treacherous, 34-hour pilgrimage that ultimately brought the group of eight by car to temporary accommodations in neighboring Poland last month was physically and emotionally difficult,…

Longer-term use of Ventavis (iloprost) as an add-on therapy significantly improved blood flow and lowered blood pressure in people with pulmonary arterial hypertension (PAH), a small study in Japan reported. Findings support this inhaled therapy’s established benefits as a pulmonary vasodilator — a medicine that  widens, or dilate,…